ArticleBMC cancer2018

Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.

Louise Hiller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.